Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Azeliragon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantex Receives FDA ODD for Azeliragon in Brain Metastasis from Breast Cancer
Details : TTP488 (azeliragon) is an oral capsule, inhibiting interactions of the receptor for advanced glycation end products with ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantex Pharmaceuticals Gets FDA Orphan Drug Status for Azeliragon in Pancreatic Cancer
Details : TTP488 (azeliragon) is an oral capsule, inhibiting interactions of the receptor for advanced glycation end products with ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Michigan Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of hospitalized patients for COVID-19 infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Azeliragon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Michigan Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of refractory to first-line treatment of metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Azeliragon,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Lenox Hill Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients newly diagnosed unmethylated glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Lenox Hill Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of RAGE with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Azeliragon,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Azeliragon in MGMT Unmethylated Glioblastoma
Details : Azeliragon is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Azeliragon
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azeliragon,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Cantex gets exclusive worldwide license for intellectual property related to the potential use of TTP488 (azeliragon), a small molecule RAGE inhibitor, to treat, prevent or alleviate cancer treatment-related cognitive decline.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 16, 2023
Lead Product(s) : Azeliragon,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Azeliragon
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Cantex obtained an exclusive worldwide license for intellectual property related to the potential use of TTP-488 (azeliragon) to treat, prevent or alleviate cancer-treatment related cognitive decline.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : Azeliragon
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Georgetown University
Deal Size : Undisclosed
Deal Type : Licensing Agreement